RCS - Destiny Pharma PLC - Presentation at ESCMID on XF-73 Nasal Gel

Destiny PharmaAnnouncement

20/08/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240820:nRST9894Aa&default-theme=true

RNS Number : 9894A  Destiny Pharma PLC  20 August 2024

Destiny Pharma plc
("Destiny Pharma" or "the Company")

 

Destiny Pharma to Deliver Presentation at the European Society of Clinical
Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use
of Post-Operative Antibiotics in Cardio-vascular Surgery Patients

 

Brighton, United Kingdom - 20 August 2024 - Destiny Pharma, a clinical stage
biotechnology company focused on the development and commercialisation of
novel medicines to prevent and cure life threatening infections, today
announced that clinical data from its Phase 2b clinical trial on XF-73 nasal
administered to cardiac surgery patients has been accepted for an oral
presentation at the European Society of Clinical Microbiology and Infectious
Disease (ESCMID) conference, the leading European conference on infectious
disease in Porto, Portugal, entitled 'meeting the challenge of antimicrobial
resistance', 17-20 September 2024.

 

S. aureus bacterial nasal carriage, (including MRSA), has been established as
an important risk factor for the development of bacteremia and surgical site
infections (SSIs) in cardio-thoracic surgery. The decolonization of S. aureus
nasal carriage prior to cardiac high-risk surgery forms part of current global
guidelines for surgical infection prevention. Mupirocin is widely used as a
nasal antibiotic for the treatment of nasal carriage of S. aureus but has
significant limitations including a lengthy five day dosing and the widespread
emergence of Mupirocin-resistant bacterial strains.

 

XF-73, is a new antibiotic with a novel mechanism of action, exhibiting fast
and potent bactericidal properties with a low propensity for engendering
bacterial resistance. It is being developed as an intranasal gel for
decolonization of S. aureus, (including MRSA), to prevent post-surgical
infections.

 

Destiny Pharma has completed a Phase 2 double-blind, randomized Phase 2
clinical trial of XF-73 nasal gel in open chest cardiac surgery patients with
confirmed nasal S. aureus carriage and has been invited to deliver a
presentation of the findings from the study at ESCMID conference. The key
findings that will be presented include;

 

·    Results demonstrated a rapid > 99% reduction in S. aureus nasal
burden 1 hr prior to surgery (-2.229 log(10) CFU/mL) in XF-73 treated patients
compared to baseline (placebo -0.014 log(10) CFU/mL), which represents a
highly statistically significant decrease, (p< 0.0001).

 

·    This level of nasal reduction was maintained for up to 6 days
post-surgery.

 

·    Significantly fewer patients in the XF-73 arm compared to the placebo
arm required post-operative antibiotics (20/43, 46.5% vs. 28/40, 70%
respectively; p=0.045)

 

Advantages of XF-73 nasal gel include: the short pre-surgical dosing, rapidity
of decolonization, remote likelihood of resistance emergence, the duration of
these effects in the perioperative period and a reduction in the use of
post-operative antibiotics. These features provide a good fit with clinical
practice (better compliance) potentially enabling infection risk reduction
peri-operatively (i.e. use for emergency procedures), enhanced flexibility for
scheduling surgeries and to augment antibiotic stewardship efforts. Phase 3
studies are being planned to evaluate and gain regulatory approval for XF-73.

 

Dr Bill Love (Chief Scientific Officer, Destiny Pharma): 'We are delighted to
have been accepted to present this compelling clinical data on XF-73 nasal at
ESCMID 2024. This is the leading European conference on antimicrobial drugs
with clinical impact and is focused on presenting new data that can make a
positive impact in tackling antimicrobial resistance (AMR).'

 

 

For further information, please contact:

 

Destiny Pharma
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

Forward looking statements

Certain information contained in this announcement, including any information
as to the company's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the company's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the company operates. The Directors of the company believe that the
expectations reflected in these statements are reasonable but may be affected
by a number of variables which could cause actual results or trends to differ
materially. Each forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future or are beyond the
company's control. Forward looking statements are not guarantees of future
performance. Even if the company's actual results of operations, financial
condition and the development of the industries in which the company operates
are consistent with the forward-looking statements contained in this document,
those results or developments may not be indicative of results or developments
in subsequent periods.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKPNFAELEFA